MEGAN SOLIS: Open Payments
NPI 1649729419 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,225 in 72 payments from 13 companies in 2025. Trend: 2023 $1,024 · 2024 $1,318 · 2025 $1,225
Food & beverage: $1,225
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $384 |
| Aimmune Therapeutics, Inc. | 9 | $157 |
| VIVUS LLC | 7 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| QOL Medical, LLC | 3 | $75 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $73 |
| Janssen Biotech, Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 6 | $52 |
| EVOKE PHARMA, INC. | 2 | $40 |
Products named: ZENPEP, RINVOQ, CREON, LINZESS, QSYMIA, Sucraid, XIFAXAN, TREMFYA.
Industry payments across TX — which companies pay providers there.
